Category: AtriCure Inc.
AtriCure says the FDA granted an investigational device exemption for a clinical trial of its AtriClip left atrial appendage exclusion device to gauge its utility in preventing stroke in patients with atrial fibrillation.
AtriCure (NSDQ:ATRC) said today that the FDA approved the launch of a clinical trial to examine whether its AtriClip device can be used to prevent strokes in patients with atrial fibrillation.
AtriCure shares are up today after the medical device company reported surging 3rd-quarter sales and raised its outlook for the rest of the year.
AtriCure (NSDQ:ATRC) shares added more than 8% today after the medical device company reported 3r-quarter sales that beat Wall Street's forecast and raised its outlook for the rest of the year.
Ohio medical device maker AtriCure pledges to make "significant investments" into research and education in efforts to improve the lives of 250,000 atrial fibrillation patients by 2020.
AtriCure and Century Medical beef up their Japanese distribution contract for surgical ablation tools, extending exclusivity until 2019.
AtriCure (NSDQ:ATRC) inked a bigger and bolder contract with its Japanese distributor Century Medical Inc., promising its partner exclusive rights for all product lines until 2019.
Despite posting losses in the 2nd quarter, AtriCure shares float on raised guidance.
AtriCure (NSDQ:ATRC) posted slightly wider 2nd-quarter losses but shares remained healthy on Wall Street after the company boosted its guidance.
Allergan fills the president's office with a company veteran.
The board of Allergan (NYSE:AGN) named Douglas Ingram president following 17 years in other upper management roles at the Irvine, Calif., drug and device maker. Ingram was most recently president and executive VP of the company's European, African and Middle East regions.
A list of some of the tax tabs for medical device companies for the medical device excise tax during Q1
In January 2013, Medical device companies began paying a 2.3% excise tax on U.S. Sales in order to pay for the Patient Protection and Affordable Care Act.
The levy is expected to generate some $30 billion over the next 10 years.
MassDevice.com is tracking the tally paid by several medical device companies, based on quarterly earnings report for the first quarter of 2013. We will update the list as more companies returns file in.
Tallies based on companies with Q1 earnings ended on March 31, 2013